Dysregulation of the spatiotemporally controlled mTOR‐driven pathway contributes to breast cancer development, progression, and drug resistance (Butt et al., 2019; Guerrero‐Zotano et al., 2016). The gene discussed is MTOR; the disease is breast carcinoma.